Nominate a UC cause or program for #GivingTuesday
For the 2023 edition of #GivingTuesday set for Tuesday, Nov. 28, the University of Cincinnati is celebrating the many ways UC and UC Health make a positive impact on the world. Marking the tenth consecutive year for the university’s participation in the national #GivingTuesday campaign, UC seeks to highlight various UC good works that significantly influence the lives of our students and members of the community.
Those with a passion for a particular UC effort or initiative can add their support in the planning stage of #GivingTuesday by nominating that cause or program to be part of the campaign. If selected, the UC Foundation will help raise funds and awareness for the initiative during the Nov. 28 event. Last year’s campaign raised $514,032 from 3,049 gifts.
Nominate your UC cause/program today!
Featured image at top: Give with heart this #GivingTuesday. Photo/UC Alumni Association.
Related Stories
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.
Study: Additional radiation for liver cancer does not increase toxicity
March 10, 2026
New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.